BR112012011710A2 - composto de espiropiperidina como antagonistas de receptor de orl-1, sua composição farmacêutica e seu uso - Google Patents
composto de espiropiperidina como antagonistas de receptor de orl-1, sua composição farmacêutica e seu usoInfo
- Publication number
- BR112012011710A2 BR112012011710A2 BR112012011710A BR112012011710A BR112012011710A2 BR 112012011710 A2 BR112012011710 A2 BR 112012011710A2 BR 112012011710 A BR112012011710 A BR 112012011710A BR 112012011710 A BR112012011710 A BR 112012011710A BR 112012011710 A2 BR112012011710 A2 BR 112012011710A2
- Authority
- BR
- Brazil
- Prior art keywords
- orl
- receptor antagonists
- pharmaceutical composition
- treatment
- spiropiperidine compound
- Prior art date
Links
- 108010020615 nociceptin receptor Proteins 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- -1 spiropiperidine compound Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000008589 Obesity Diseases 0.000 abstract 2
- 206010033307 Overweight Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382245 | 2009-11-16 | ||
| US29862810P | 2010-01-27 | 2010-01-27 | |
| PCT/US2010/056449 WO2011060217A1 (en) | 2009-11-16 | 2010-11-12 | Spiropiperidine compounds as orl-1 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012011710A2 true BR112012011710A2 (pt) | 2016-03-01 |
Family
ID=41800752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012011710A BR112012011710A2 (pt) | 2009-11-16 | 2010-11-12 | composto de espiropiperidina como antagonistas de receptor de orl-1, sua composição farmacêutica e seu uso |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20120214784A1 (enExample) |
| EP (1) | EP2501704B1 (enExample) |
| JP (1) | JP5723381B2 (enExample) |
| KR (1) | KR101368130B1 (enExample) |
| CN (1) | CN102666550B (enExample) |
| AU (1) | AU2010319400B2 (enExample) |
| BR (1) | BR112012011710A2 (enExample) |
| CA (1) | CA2781041C (enExample) |
| DK (1) | DK2501704T3 (enExample) |
| EA (1) | EA020391B1 (enExample) |
| ES (1) | ES2436241T3 (enExample) |
| HR (1) | HRP20130969T1 (enExample) |
| MX (1) | MX2012005690A (enExample) |
| PL (1) | PL2501704T3 (enExample) |
| PT (1) | PT2501704E (enExample) |
| RS (1) | RS53017B (enExample) |
| SI (1) | SI2501704T1 (enExample) |
| WO (1) | WO2011060217A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX388468B (es) | 2009-12-04 | 2025-03-20 | Sunovion Pharmaceuticals Inc | Compuestos multicíclicos y métodos de uso de los mismos. |
| TWI582096B (zh) * | 2011-12-06 | 2017-05-11 | 美國禮來大藥廠 | 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物 |
| TW201416370A (zh) | 2012-07-31 | 2014-05-01 | Lilly Co Eli | 用於治療焦慮之ｏｒｌ－１受體拮抗劑 |
| EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| AR105821A1 (es) * | 2015-09-09 | 2017-11-15 | Lilly Co Eli | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T |
| WO2018023070A1 (en) | 2016-07-29 | 2018-02-01 | Sunovion Pharmaceuticals, Inc. | Compounds and compositions and uses thereof |
| MY199446A (en) | 2016-07-29 | 2023-10-28 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| RU2019106494A (ru) | 2016-08-10 | 2020-09-14 | Байер Кропсайенс Акциенгезельшафт | Замещенные 2-гетероциклил-имидазолил-карбоксамиды в качестве средств для борьбы с вредителями |
| AU2018220509B2 (en) | 2017-02-16 | 2022-04-28 | Sumitomo Pharma America, Inc. | Methods of treating schizophrenia |
| WO2018160547A1 (en) * | 2017-03-02 | 2018-09-07 | Eli Lilly And Company | Compounds useful for inhibiting ror-gamma-t |
| SI3589638T1 (sl) | 2017-03-02 | 2021-08-31 | Eli Lilly And Company | Spojine uporabne pri inhibiciji ROR-GAMMA-T |
| KR20200036008A (ko) | 2017-08-02 | 2020-04-06 | 선오비온 파마슈티컬스 인코포레이티드 | 이소크로만 화합물 및 이의 용도 |
| MY208150A (en) | 2018-02-16 | 2025-04-18 | Sunovion Pharmaceuticals Inc | Salts, crystal forms, and production methods thereof |
| US11618746B2 (en) | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| CN113784755B (zh) | 2019-03-14 | 2024-05-10 | 赛诺维信制药公司 | 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物 |
| EP3766879A1 (en) | 2019-07-19 | 2021-01-20 | Basf Se | Pesticidal pyrazole derivatives |
| JP7781768B2 (ja) | 2020-04-14 | 2025-12-08 | スミトモ・ファーマ・アメリカ・インコーポレイテッド | 神経学的および精神障害の治療方法 |
| MX2023002269A (es) | 2020-08-26 | 2023-05-16 | Vertex Pharma | Inhibidores de apol1 y metodos para usar los mismos. |
| CA3251050A1 (en) * | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003095427A1 (en) | 2002-05-10 | 2003-11-20 | Taisho Pharmaceutical Co.,Ltd. | Spiro-ring compound |
| WO2005016913A1 (en) * | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
| DE10360792A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| BRPI0509377A (pt) * | 2004-03-29 | 2007-09-11 | Pfizer | compostos de ácido alfa arila ou heteroaril metil beta piperidino propanóico como antagonistas do receptor orl1 |
| DE102004039382A1 (de) * | 2004-08-13 | 2006-02-23 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| EP1890696A4 (en) * | 2005-06-02 | 2010-05-05 | Janssen Pharmaceutica Nv | Suitable as new ORL-1 receptor modulators are 3-pyrolytic indolyl derivatives |
-
2010
- 2010-11-12 PT PT107824864T patent/PT2501704E/pt unknown
- 2010-11-12 CN CN201080051845.3A patent/CN102666550B/zh not_active Expired - Fee Related
- 2010-11-12 ES ES10782486T patent/ES2436241T3/es active Active
- 2010-11-12 EP EP10782486.4A patent/EP2501704B1/en active Active
- 2010-11-12 CA CA2781041A patent/CA2781041C/en not_active Expired - Fee Related
- 2010-11-12 EA EA201290355A patent/EA020391B1/ru not_active IP Right Cessation
- 2010-11-12 SI SI201030389T patent/SI2501704T1/sl unknown
- 2010-11-12 BR BR112012011710A patent/BR112012011710A2/pt active Search and Examination
- 2010-11-12 US US13/504,176 patent/US20120214784A1/en not_active Abandoned
- 2010-11-12 PL PL10782486T patent/PL2501704T3/pl unknown
- 2010-11-12 AU AU2010319400A patent/AU2010319400B2/en not_active Ceased
- 2010-11-12 MX MX2012005690A patent/MX2012005690A/es active IP Right Grant
- 2010-11-12 KR KR1020127012503A patent/KR101368130B1/ko not_active Expired - Fee Related
- 2010-11-12 DK DK10782486.4T patent/DK2501704T3/da active
- 2010-11-12 HR HRP20130969AT patent/HRP20130969T1/hr unknown
- 2010-11-12 JP JP2012538997A patent/JP5723381B2/ja active Active
- 2010-11-12 RS RS20130484A patent/RS53017B/sr unknown
- 2010-11-12 WO PCT/US2010/056449 patent/WO2011060217A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013510870A (ja) | 2013-03-28 |
| RS53017B (sr) | 2014-04-30 |
| AU2010319400A1 (en) | 2012-06-07 |
| JP5723381B2 (ja) | 2015-05-27 |
| KR20120082927A (ko) | 2012-07-24 |
| PT2501704E (pt) | 2013-12-05 |
| WO2011060217A1 (en) | 2011-05-19 |
| EP2501704A1 (en) | 2012-09-26 |
| EA201290355A1 (ru) | 2012-10-30 |
| PL2501704T3 (pl) | 2014-02-28 |
| MX2012005690A (es) | 2012-06-13 |
| EA020391B1 (ru) | 2014-10-30 |
| CN102666550B (zh) | 2015-07-15 |
| US20120214784A1 (en) | 2012-08-23 |
| CN102666550A (zh) | 2012-09-12 |
| CA2781041A1 (en) | 2011-05-19 |
| ES2436241T3 (es) | 2013-12-27 |
| DK2501704T3 (da) | 2013-10-14 |
| SI2501704T1 (sl) | 2013-11-29 |
| KR101368130B1 (ko) | 2014-02-27 |
| HRP20130969T1 (hr) | 2013-11-22 |
| CA2781041C (en) | 2015-01-06 |
| EP2501704B1 (en) | 2013-09-18 |
| AU2010319400B2 (en) | 2013-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012011710A2 (pt) | composto de espiropiperidina como antagonistas de receptor de orl-1, sua composição farmacêutica e seu uso | |
| BRPI0508820B8 (pt) | compostos moduladores de receptor de opióide e composição que os compreende | |
| BR112012007102A2 (pt) | compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico | |
| BR112015012555A2 (pt) | derivados de benzimidazol como antagonistas de ep4 | |
| BR112014030060A2 (pt) | compostos de tetra-hidropirazolopirimidina | |
| BR112012024017A2 (pt) | compostos derivados de triazina dissubstituída farmaceuticamemnte ativios, composição farmacêutica, método para a síntese destes e uso dos mesmos | |
| BR112014030678A2 (pt) | formas cristalinas de um modulador de receptor de androgênio | |
| PH12012500969A1 (en) | Spiropiperidine compounds as orl-1 receptor antagonists | |
| DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| GT201400009A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk | |
| CL2013001677A1 (es) | Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia. | |
| BR112014014184A2 (pt) | triazolopiridinas substituídas e seu uso como inibidores de ttk | |
| BR112012013431A8 (pt) | composto, composição farmacêutica e seu uso | |
| BR112014011850A8 (pt) | Derivados de aminopirimidina, seus usos, e composição farmacêutica | |
| BR112012007234A2 (pt) | combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação | |
| BR112014018475A8 (pt) | Compostos de imidazopirrolidinona, suas formas cristalinas e seu uso, e composição farmacêutica | |
| DOP2007000078A (es) | Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
| CR20120574A (es) | NUEVOS DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENÉRGICOS ß2 Y COMO ANTAGONISTAS MUSCARÍNICOS M3 | |
| CO6450612A2 (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
| BRPI0923231B1 (pt) | anticorpo anti-cmet, composição que compreende, e usos do anticorpo e da composição. | |
| BR112013006344A2 (pt) | lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas | |
| BR112013000059A2 (pt) | derivados de piperidina e seus usos para o tratamento de distúrbios metabólicos | |
| BRPI0907789A2 (pt) | derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos | |
| BR112012027197A2 (pt) | combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas | |
| UY31922A (es) | Compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |